Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + lenvatinib with SBRT and HAIC for unresectable HCC with main portal vein tumor thrombus
ChiCTR2200066334Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Hainan Medical University
- Start
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Hainan Medical University. Primary endpoint: 6-month overall survival rate. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
toripalimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200066334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066334.